McKesson Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for McKesson Corporation for the quarter and nine months ended December 31, 2007. The company operates in two primary segments: Distribution Solutions (pharmaceutical and medical-surgical distribution) and Technology Solutions (healthcare software and services). The fiscal year ends March 31.
Key Financial Metrics
| Metric | Quarter Ended Dec 31, 2007 | Nine Months Ended Dec 31, 2007 |
|---|---|---|
| Revenues | $26,494 million | $75,472 million |
| Net Income | $201 million | $683 million |
| Diluted EPS | $0.68 | $2.28 |
| Gross Profit Margin | 4.54% | 4.72% |
| Operating Cash Flow (9mo) | ($47) million | ($47) million |
| Cash and Equivalents | $1,436 million | $1,436 million |
| Total Debt (Current + Long-Term) | $1,949 million | $1,949 million |
| Working Capital | $2,837 million | $2,837 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 15% for the quarter and 10% for the nine-month period compared to the prior year, driven by growth in Distribution Solutions and acquisitions (OTN and Per-Se).
- Profitability Decline (Quarterly): Net income decreased 17% to $201 million for the quarter. This was primarily due to $41 million in pre-tax charges related to legal reserves, severance, and asset impairments.
- Profitability Increase (Nine Months): Net income increased 4% to $683 million for the nine-month period, aided by an $83 million tax credit related to the deductibility of the securities litigation settlement.
- Cash Flow: Operating cash flow turned negative ($47 million used) for the nine months ended Dec 31, 2007, compared to $555 million provided in the prior year. This shift was largely due to the release of $962 million in restricted cash for the securities litigation settlement and increased working capital requirements (receivables and inventory).
- Acquisitions: Significant acquisitions included Oncology Therapeutics Network (OTN) for ~$531 million and Per-Se Technologies for ~$1.8 billion.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes quarterly earnings declines to specific one-time charges ($41 million pre-tax) and increased share-based compensation. The nine-month performance benefited from lower effective tax rates and the reversal of tax reserves related to the securities litigation.
- Capital Allocation: The company repurchased $926 million of stock in the first nine months of 2008. A $1.0 billion repurchase plan approved in April 2007 had $86 million remaining, and a new $1.0 billion plan approved in September 2007 remains fully available.
- Legal and Regulatory Risks:
- Securities Litigation: The $962 million settlement for the Consolidated Securities Litigation Action was finalized and paid, removing the liability and restricted cash from the balance sheet.
- Government Investigations: The company is in discussions with the DEA and US Attorneys regarding reporting of controlled substances orders (2005-2007). Management believes reserves are adequate.
- Antitrust Litigation: Ongoing class action lawsuits regarding pharmaceutical pricing (New England Carpenters Health Benefits Fund) remain pending with trial dates set for 2009.
- Discontinued Operations: The divestiture of the Acute Care business resulted in a $64 million after-tax loss for the nine-month period, primarily due to a $79 million goodwill write-off.
Key Facts for Investor Verification
- One-Time Charges: Verify the sustainability of earnings by excluding the $41 million in pre-tax charges (legal reserves, severance, impairments) recorded in the third quarter.
- Tax Rate Volatility: Monitor the effective tax rate, which was significantly impacted by an $83 million credit regarding the tax deductibility of the securities litigation settlement.
- Working Capital Intensity: Assess the impact of inventory and receivable build-up on future operating cash flows, which turned negative for the nine-month period.
- Acquisition Integration: Evaluate the financial contribution and integration progress of the Per-Se ($1.8B) and OTN ($531M) acquisitions.
- Legal Reserves: Review the adequacy of reserves for ongoing government investigations (DEA) and antitrust litigation, as outcomes could materially impact future results.